Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Ocular Therapeut
(NQ:
OCUL
)
6.120
-0.150 (-2.39%)
Streaming Delayed Price
Updated: 10:10 AM EDT, May 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Ocular Therapeut
< Previous
1
2
3
4
5
6
7
Next >
Ocular Therapeutix™ Announces FDA Approval of Supplemental New Drug Application (sNDA) for DEXTENZA® (dexamethasone ophthalmic insert) 0.4 mg for Intracanalicular Use for the Treatment of Ocular Itching Associated with Allergic Conjunctivitis
October 11, 2021
From
Ocular Therapeutix, Inc.
Via
Business Wire
28 Stocks Moving In Monday's Mid-Day Session
October 11, 2021
Gainers Protagonist Therapeutics, Inc. (NASDAQ: PTGX) shares surged 85% to $33.78. The FDA removed the full clinical hold on Protagonist Therapeutics’ rusfertide clinical...
Via
Benzinga
Exposures
Product Safety
Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates
October 01, 2021
Following a mixed month for regulatory approvals, biotech investors now turn toward a month of plenty as far as Food and Drug Administration decisions are concerned. Four new...
Via
Benzinga
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
August 08, 2021
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,...
Via
Benzinga
Exposures
Product Safety
Ocular Therapeutix™ Announces Appointment of Karen-Leigh Edwards as Senior Vice President of Technical Operations
September 28, 2021
From
Ocular Therapeutix, Inc.
Via
Business Wire
Ocular Therapeutix™ Appoints Merilee Raines to Its Board of Directors
September 22, 2021
From
Ocular Therapeutix, Inc.
Via
Business Wire
Ocular Therapeutix™ Updates Monthly In-Market Unit Sales of DEXTENZA® Billable Inserts
September 13, 2021
From
Ocular Therapeutix, Inc.
Via
Business Wire
Ocular Therapeutix™ to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
September 07, 2021
From
Ocular Therapeutix, Inc.
Via
Business Wire
This Exciting Biopharma Could Earn You 55% in 12 Months
August 22, 2021
When patients see more clearly, so too should investors.
Via
The Motley Fool
4 Reasons I Just Bought Ocular Therapeutix Stock
August 21, 2021
This company's drug delivery technology just isn't getting the appreciation it deserves right now.
Via
The Motley Fool
Ocular Therapeutix™ to Present at the H.C. Wainwright Ophthalmology Virtual Conference
August 10, 2021
From
Ocular Therapeutix, Inc.
Via
Business Wire
Ocular Therapeutix™ Reports Second Quarter 2021 Financial Results and Business Update
August 09, 2021
From
Ocular Therapeutix, Inc.
Via
Business Wire
Ocular Therapeutix, Regeneron Cull Aflibercept Agreement For Retinal Diseases
August 06, 2021
Ocular Therapeutix Inc (NASDAQ: OCUL) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) have terminated the option and license agreement collaboration. The...
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
August 05, 2021
Gainers Sensus Healthcare (NASDAQ:SRTS) ...
Via
Benzinga
Ocular Therapeutix™ Announces Termination of the Collaboration with Regeneron to Develop a Sustained-Release Formulation of Aflibercept for the Treatment of Wet AMD and other Serious Retinal Diseases
August 05, 2021
From
Ocular Therapeutix, Inc.
Via
Business Wire
Earnings Scheduled For August 9, 2021
August 09, 2021
Companies Reporting Before The Bell • Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $1.57 per share on revenue of $215.17 million. •...
Via
Benzinga
The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO
August 06, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 5) Alkermes plc (NASDAQ: ALKS)...
Via
Benzinga
Ocular Therapeutix™ Announces First Patient Dosed in U.S.-based Phase 1 Clinical Trial of OTX-TKI for the Treatment of Wet Age-Related Macular Degeneration
July 29, 2021
From
Ocular Therapeutix, Inc.
Via
Business Wire
Ocular Therapeutix™ To Report Second Quarter 2021 Financial Results
July 28, 2021
From
Ocular Therapeutix, Inc.
Via
Business Wire
Ocular Therapeutix™ To Present Clinical Data at the 2021 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
July 23, 2021
From
Ocular Therapeutix, Inc.
Via
Business Wire
The Daily Biotech Pulse: Acorda Spikes On Distribution Deal, Alzamend Soars On Data, Pfizer-BioNTech To Supply More Vaccine Doses, 3 IPOs
July 23, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 22) Bio-Techne Corporation (...
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
July 22, 2021
Gainers Xenetic Biosciences (NASDAQ:XBIO...
Via
Benzinga
Ocular Therapeutix™ Announces Second Quarter 2021 Preliminary Net Product Revenue of $11.7 Million
July 22, 2021
From
Ocular Therapeutix, Inc.
Via
Business Wire
Ocular Therapeutix™ and Mosaic Biosciences Enter into Strategic Discovery Collaboration Targeting the Treatment of Dry Age-Related Macular Degeneration
June 29, 2021
From
Ocular Therapeutix, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Tuesday's After-Market Session
June 08, 2021
Gainers Aethlon Medical (NASDAQ:AEMD) sto...
Via
Benzinga
Ocular Therapeutix™ to Participate at Three Upcoming Investor Conferences
May 26, 2021
From
Ocular Therapeutix, Inc.
Via
Business Wire
Ocular Therapeutix™ Reports First Quarter 2021 Financial Results and Business Update
May 05, 2021
From
Ocular Therapeutix, Inc.
Via
Business Wire
CORRECTING and REPLACING Ocular Therapeutix™ To Present Pre-Clinical and Clinical Data at the 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
May 03, 2021
From
Ocular Therapeutix, Inc.
Via
Business Wire
Ocular Therapeutix™ Fulfills Post-Marketing Approval Requirements for ReSure® Sealant
May 03, 2021
From
Ocular Therapeutix, Inc.
Via
Business Wire
The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues
May 05, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 4) AbbVie Inc. (NYSE: ABBV)...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.